Latest Research in Acute Myeloid Leukemia Research
12 research papers · 0.1 average citations · 2026 median publication year
Top Research Topics in Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research — 11 papers
- Cell death mechanisms and regulation — 1 papers
Highest-Cited Papers
- Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia (1 citations)
- Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
- Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance
- CD84 expression stratifies venetoclax response and reveals a targetable vulnerability in resistant acute myeloid leukemia
- Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium
- Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients
- Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study
- Retrospective evaluation of venetoclax-based regimen in newly diagnosed and relapsed/refractory acute myeloid leukemia: Efficacy determinants, survival outcomes, and model validation
- Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies
- The introduction of hypomethylation agents and venetoclax into standard care for older patients with acute myeloid leukemia: A retrospective real-world analysis of feasibility, safety, and effectiveness from an outpatient hematology center.
- Modified azacitidine plus cytarabine versus traditional cytarabine in patients with newly diagnosed acute myeloid leukaemia: a retrospective and propensity score matched analysis
- Older Age, STAG2 , and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents